Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020
July 08 2020 - 8:37AM
Business Wire
Program to feature presentation from Dr. Murray
Stein, Distinguished Professor of Psychiatry at UCSD and
board-certified psychiatrist
Aptinyx expects data from exploratory Phase 2
study of NYX-783 in PTSD in late 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that it will
host a virtual R&D Day focused on the company’s development
efforts in post-traumatic stress disorder (PTSD) on Wednesday,
August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET.
The meeting will feature a presentation from Murray B. Stein MD,
MPH, FRCPC. Dr. Stein is Distinguished Professor of Psychiatry and
Family Medicine & Public Health and Vice Chair for Clinical
Research in Psychiatry at the University of California San Diego
(UCSD). He is also a Staff Psychiatrist at the VA San Diego
Healthcare System. Dr. Stein will be available to answer questions
following the event.
The R&D day will also feature presentations by members of
Aptinyx’s management team, who will provide an overview of the
progress of NYX-783, the company’s novel NMDA receptor modulator in
clinical development for the treatment of PTSD. Last month, Aptinyx
announced the completion of enrollment in its ongoing Phase 2
exploratory study of NYX-783 in patients with PTSD. The company
anticipates reporting data from the study in late 2020.
Video Webcast Information
A live video webcast of the event will be available on the
“Events and Presentations” page in the “Investors & Media”
section of Aptinyx’s website at https://ir.aptinyx.com. A replay of
the webcast will be archived on Aptinyx’s website following the
event.
About Post-Traumatic Stress Disorder
Approximately eight and a half million people in the United
States suffer from PTSD, which is characterized by intrusive
symptoms, avoidance, negative alteration in cognition and mood,
hyperarousal, and/or arousal alterations following the experience
of trauma. PTSD can result from various forms of trauma, including
combat exposure, car accidents, sexual or other physical assault,
abuse, natural disasters, and others. The lifetime prevalence of
PTSD is approximately seven percent in the general population but
is much higher in populations at risk for exposure to trauma, such
as military service members and first responders. In addition to
the challenges associated with the direct symptoms, PTSD sufferers
have a higher rate of suicide and often struggle with simultaneous
addiction, leading to an even greater social and economic burden of
the disorder. Available therapeutic options are limited, including
only two approved conventional SSRI antidepressants, which have
limited efficacy, undesirable side effects, and target only the
symptoms of PTSD, not the underlying disorder itself.
About NYX-783
NYX-783 is a novel, oral NMDA receptor modulator currently in
Phase 2 development for the treatment of post-traumatic stress
disorder (PTSD). In preclinical studies of NYX-783, particularly
strong results were observed in psychiatric models, models of fear
extinction, and models of substance abuse. In a Phase 1 clinical
study of NYX-783, ample central nervous system exposure was
observed and the product candidate demonstrated a favorable safety
and tolerability profile, with no serious adverse effects, across a
wide dose range. The U.S. Food and Drug Administration has granted
Fast Track designation to the development of NYX-783 for the
treatment of PTSD.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment associated with Parkinson’s disease. Aptinyx is also
advancing additional compounds from its proprietary discovery
platform, which continues to generate a rich and diverse pipeline
of small-molecule NMDA receptor modulators with the potential to
treat an array of neurologic disorders. For more information, visit
www.aptinyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, including future plans
or expectations for NYX-783 and potential therapeutic effects of
NYX-783, expectations regarding the design, implementation, timing,
and success of its current and potential clinical studies of
NYX-783, the timing for the company’s receipt and announcement of
data from its exploratory study of NYX-783, and expectations
regarding its preclinical development activities. Risks that
contribute to the uncertain nature of the forward-looking
statements include: the effect of COVID-19 on our business and
financial results, including with respect to disruptions to our
clinical trials, business operations, and ability to raise
additional capital; the success, cost, and timing of the company’s
product candidate development activities and planned clinical
studies; the company’s ability to execute on its strategy; that
positive results from a clinical study may not necessarily be
predictive of the results of future or ongoing clinical studies;
regulatory developments in the United States and foreign countries;
the company’s estimates regarding expenses, future revenue, and
capital requirements; as well as those risks and uncertainties set
forth in the company’s most recent annual report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200708005275/en/
Investor & Media Contact: Nick Smith Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024